Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Sarcoma, Endometrial Stromal 1Pancreatic Neoplasms 1Adrenocortical Adenoma 1

Interventions

Gemcitabine 295Fluorouracil 82Oxaliplatin 81130-nm albumin-bound paclitaxel 68Capecitabine 60Leucovorin 56Albumin-Bound Paclitaxel 54Radiotherapy 51Irinotecan 44Taxes 37Cisplatin 36Erlotinib Hydrochloride 34Radiosurgery 33pembrolizumab 29Docetaxel 27S 1 (combination) 26Bevacizumab 23folfirinox 22Nivolumab 21Magnetic Resonance Spectroscopy 17Cyclophosphamide 17Cetuximab 17irinotecan sucrosofate 16Radiation 16Drug Therapy 15Surgical Procedures, Operative 14Specimen Handling 11Biopsy 11durvalumab 10Paclitaxel 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Pancreatic Neoplasms × Postmortem Imaging × Clear all
NCT06906562 2026-02-17

A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations

Ohio State University Comprehensive Cancer Center

Phase 2 Recruiting
40 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡